Apollomics Inc. Class A Ordinary Shares (APLM)
Apollomics Inc. is a biotechnology company focused on the development of innovative cancer therapies. It specializes in the discovery and advancement of immuno-oncology and targeted treatments, aiming to address unmet medical needs in oncology. The company's efforts include the development of clinical-stage drug candidates and leveraging its expertise in antibody engineering and immunology.
Company News
Apollomics Inc. reversed its wind-up plans after receiving $4.1 million in PIPE investments, appointed a new board and management team, and remains committed to continuing its global clinical trials for APL-101 (vebreltinib), a targeted oncology therapy.
Shares of Salesforce, Inc. (NYSE: CRM) shares surged in pre-market trading after the company reported third-quarter financial results and issued FY24 guidance above estimates. Salesforce said third-quarter revenue increased 11% year-over-year to $8.72 billion, versus the consensus estimate of $8.72 billion, according to Benzinga Pro. The compan...
The company just went public in March and recently received coverage and a buy rating from an analyst.